Breast Cancer | Specialty

ASCENT-03 Data Show Consistent Safety With Sacituzumab Govitecan in Previously Untreated Advanced TNBC

December 16th 2025

Sacituzumab govitecan showed manageable safety vs chemotherapy in first-line TNBC, with fewer dose changes and faster AE resolution.

Sentinel Lymph Node Biopsy Omission Shows Feasibility in Select HR+ Breast Cancer

December 15th 2025

Omitting sentinel lymph node biopsy displayed noninferiority in select older patients with hormone receptor–positive breast cancer.

RAD51-Based HRD Test Could Help Refine Patient Selection for Olaparib in BRCA1/2- or PALB2-Mutant, HER2– Breast Cancer

December 13th 2025

RAD51 may serve as a functional biomarker to help guide olaparib use in HER2-negative metastatic breast cancer harboring BRCA1/2 or PALB2 mutations.

Imlunestrant With/Without Abemaciclib Maintains PFS, OS Benefit in ER+/HER2– Breast Cancer

December 12th 2025

Imlunestrant alone or in combination with abemaciclib significantly improved PFS in ER-positive and HER2-negative breast cancer.

Neoadjuvant Niraparib Plus Dostarlimab Delivers 50% pCR Rate in BRCA+ or PALB2+ TNBC

December 12th 2025

Neoadjuvant niraparib plus dostarlimab led to pathologic complete responses in BRCA- or PALB2-mutated triple-negative breast cancer.

Dr Mayer on Efficacy Findings With Giredestrant Plus Everolimus in ER+/HER2– Advanced Breast Cancer

December 12th 2025

Erica Mayer, MD, MPH, discusses giredestrant plus everolimus vs physician’s choice of endocrine therapy plus everolimus in ER+, HER2-negative locally advanced or metastatic breast cancer.

Giredestrant-Based Combo Boosts PFS Across Subgroups in Advanced ER+/HER2– Breast Cancer After CDK4/6 Inhibition

December 12th 2025

Giredestrant plus everolimus improved PFS across subgroups in ER-positive/HER2-negative advanced breast cancer.

Sacituzumab Govitecan Plus Pembrolizumab Yields Predictable, Manageable Safety Profile in TNBC

December 12th 2025

Sacituzumab govitecan combined with pembrolizumab showed a manageable safety profile with lower TEAE discontinuation rates in TNBC.

Menopausal HRT Does Not Influence Breast Cancer Risk in Women Harboring BRCA Variants

December 12th 2025

Menopausal hormone replacement therapy was not associated with an increased risk of breast cancer in women with BRCA mutations.

MRD Detection With Novel ctDNA Assay Helps Determine Distant Recurrence Risk in TNBC

December 12th 2025

MRD as detected by a novel tumor-informed ctDNA assay helped identify patients with TNBC who were at higher risk for distant recurrence after surgery.

Gedatolisib Plus Fulvestrant ± Palbociclib Is a Potential New SOC in HR+ PIK3CA Wild-Type Advanced Breast Cancer

December 12th 2025

Gedatolisib regimens showed PFS benefits irrespective of prior treatment duration in HR-positive, HER2-negative PIK3CA wild-type advanced breast cancer.

Dr Yap on Saruparib/Camizestrant in Advanced ER+, HER2-Negative or HER2-Low Breast Cancer

December 12th 2025

Long-Term PALLAS Data Show No Adjusted OS Difference With Adjuvant Palbociclib in HR+/HER2– Breast Cancer

December 12th 2025

An adjusted OS analysis showed no OS difference with the addition of adjuvant palbociclib in HR-positive/HER2-negative breast cancer.

Camizestrant Switch Plus CDK4/6 Inhibition Continues to Outperform SOC in HR+/HER2– Breast Cancer

December 12th 2025

Camizestrant plus continued CDK4/6 inhibition led to clinically meaningful improvements in PFS, PFS2, TTFST, TTSSS, and chemotherapy/ADC-free survival vs SOC.

Elacestrant-Based Combinations Show Efficacy, Safety in ER+, HER2-Negative Breast Cancer

December 12th 2025

Elacestrant plus abemaciclib or everolimus was safe and showed preliminary efficacy in ER-positive, HER2-negative advanced breast cancer.

Alpelisib Plus Fulvestrant Hits Primary PFS End Point in CDK4/6 Inhibitor–Pretreated, PIK3CA-Mutant, HR+/HER2– Breast Cancer

December 12th 2025

Alpelisib plus fulvestrant improved PFS vs fulvestrant alone in PIK3CA-mutated, hormone receptor–positive/HER2-negative advanced breast cancer.

CAPItello-291 Analysis Reveals Potential Utility of PIK3CA/AKT1/PTEN Alteration Detection Via ctDNA in Advanced HR+ Breast Cancer

December 11th 2025

Circulating tumor DNA could represent a minimally invasive approach for detecting AKT pathway alterations in hormone receptor–positive breast cancer.

Less Invasive Axillary Staging Yields Noninferior 3-Year Axillary RFS vs ALND in Node-Negative Breast Cancer

December 11th 2025

Axillary RFS at 3 years was noninferior with less vs more invasive staging procedures in node-negative breast cancer after neoadjuvant chemotherapy.

Dr Punie on Patient-Reported Outcomes With Sacituzumab Govitecan vs Chemotherapy in Advanced TNBC

December 11th 2025

Kevin Punie, MD, discusses PRO data from the phase 3 ASCENT-03 trial.

Dr Rugo on Elacestrant-Based Combos in ER+/HER2– Locally Advanced or Metastatic Breast Cancer

December 11th 2025

Hope S. Rugo, MD, discusses an open-label umbrella study evaluating elacestrant in combination with everolimus or abemaciclib in ER-positive/HER2-negative advanced breast cancer.